ArticleCureus2022
Prognostic Value of Positron Emission Tomography in Advanced Cholangiocarcinoma: A Single-Institution Study and Literature Review.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 0 citations in OpenAlex.
- Survival after pulmonary metastasectomy for pancreatobiliary carcinomas: insights from a nationwide multicenter database.Surgery today · 2026Article
- The Impact ofMolecular imaging and radionuclide therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholangiocarcinoma is an uncommon malignancy in Western countries. Previous studies from mostly Asian countries have suggested the prognostic value of 18F-fluorodeoxyglucose positron-emission tomography integrated with computerized tomography (PET/CT) for advanced cholangiocarcinoma. Here, we investigated the prognostic value of PET/CT at our institution.
methodsA retrospective cohort study based on medical record review was conducted for patients with advanced cholangiocarcinoma who underwent treatment from January 2009 to January 2019 at a large academic institution in the United States. The outcomes of interest were overall survival. Multivariable analyses were performed to characterize the relationship between survival and the highest maximum standardized uptake value (SUVmax) from baseline PET/CT scans.
resultsAnalyses included data from 61 patients. The median age was 68.9 years and 87% of patients were White. The median highest SUVmax was 8.7 (range: background value to 22.8). In a multivariable analytic model including SUVmax, patient demography, and baseline laboratory parameters, SUVmax was identified as one of the independent predictors of survival higher SUVmax significantly predicted worse survival, with hazard ratio 2.26 (95% CI: 1.07-4.75,
conclusionIn this single-institution retrospective analysis, we found that baseline SUVmax was one of the significant prognostic factors for patients with advanced cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.